Atrial Fibrillation study: Apixaban vs Rivaroxaban
Official title COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
ClinicalTrials.gov ID: NCT04642430
What this study is testing
What is Apixaban?
an investigational oral blood thinner being studied as a potential treatment for atrial fibrillation is designed to block factor Xa, reducing the formation of blood clots
Also referred to as Eliquis.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out which of the two blood thinners causes fewer bleeding problems in patients with non‑valvular atrial fibrillation.
- Who it's for
- Adults who have non‑valvular atrial fibrillation.
- What's involved
- Participants will be randomly assigned to take either apixaban or rivaroxaban and will have regular visits to check for any bleeding or other side effects.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old
- Confirmed new diagnosis of AF on ECG with an indication to start anticoagulation according to Canadian Cardiovascular Society guidelines
You likely can't join if
- Creatinine clearance =\<15 ml/min calculated using the Cockcroft-Gault formula
- active bleeding
- history of mechanical valve
- other indication for anticoagulation (e.g. mechanical valves, venous thrombosis)
- dual antiplatelet agent use
- known liver disease with coagulopathy
See the full eligibility criteria
- Age ≥ 18 years old
- Confirmed new diagnosis of AF on ECG with an indication to start anticoagulation according to Canadian Cardiovascular Society guidelines
- Creatinine clearance =\<15 ml/min calculated using the Cockcroft-Gault formula
- active bleeding
- history of mechanical valve
- other indication for anticoagulation (e.g. mechanical valves, venous thrombosis)
- dual antiplatelet agent use
- known liver disease with coagulopathy
- use of contraindicated medications (strong inducers/inhibitors of CYP 3A4/5, P-glycoprotein)
- pregnancy or breastfeeding
The study team makes the final eligibility decision.
Where it is enrolling
- Halifax, Nova Scotia, Canada
- Kingston, Ontario, Canada
- Ottawa, Ontario, Canada
- Gatineau, Quebec, Canada
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Halifax, Nova Scotia, Canada; Kingston, Ontario, Canada; Ottawa, Ontario, Canada; Gatineau, Quebec, Canada; Montreal, Quebec, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.